ADCs have huge potential in treating challenging diseases such as cancer. However, it is essential that all necessary equipment, steps, and precautions are in place to en¬sure their safe handling.
Sino Biological, a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical is pleased to announce a CRO services partnership with Ainnocence, Inc. of San Jose, California.
The life sciences location of Austria has gained considerable momentum since the founding of the very first Austrian biotech company Intercell at the turn of the millennium. Today the who’s who of the biotech sector relies on Austria, in particular on its capital city of Vienna.
Saxony has established itself as a dynamic life-sciences hub and provides an attractive environment for investors and start-ups The SaxoCell’ network and CMI major research centre are furthering innovations in cell and gene therapy Interdisciplinary co-operation offers huge growth opportunities for applications such as point-of-care diagnostics Leipzig as host of BIO-Europe 2022
Sino Biological, Inc., a biotechnology company listed on ChiNext (SZSE: 301047), provides biological research reagents and related technical contract research services, is pleased to announce its physical geographic expansion, adding a new location in Houston, Texas.
Sino Biological, Inc. has recently deposited reagents for the Omicron variant, including recombinant proteins to Spike and Nucleocapsid, and antibody products to a central repository for reagents to support infectious disease research. With the addition of the Omicron products to previously deposited array of SARS-CoV-2 reagents, researchers can readily get access to them by registering with BEI Resources.
Abstract: This report provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly. Criteria includes:
Abstract: This report provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly. Criteria includes:
Sino Biological, Inc. announced today that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus, which quickly raised concerns around the world because of the high number of mutations it carries, especially the 30-plus mutations on the Spike protein.
The COVID-19 pandemic created exceptional circumstances for virologists. To speed up the process from initial basic experiments to the final clinical application, appropriate reagents are required. Isolation of SARS-CoV-2-specific T cells via the MHC Streptamer® approach yields label-free, fully functional cells, making this method a valuable tool for high quality research.